Interleukin-1 beta Antibodies

Interleukin-1 beta (IL1B)

Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production.

Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells (PubMed:10653850).

Gene Information

Human
Gene Name:	IL1B
Uniprot:	P01584
Entrez:	3553

Family

Belongs to:
IL-1 family

Alternative Names

catabolin; IL1 beta; IL-1 beta; IL-1; IL1B; IL-1b; IL1-BETA; IL-1F2; IL1F2IL-1 beta; interleukin 1, beta; interleukin-1 beta; preinterleukin 1 beta; pro-interleukin-1-beta

Molecular Weight

Mass (kDA):
30.748 kDA

Genomic Context

Human
Location:	2q14.1
Sequence:	2; NC_000002.12 (112829751..112836843, complement)

Tissue Specificity

Expressed in activated monocytes/macrophages (at protein level).

Subcellular Localizations

Cytoplasm, cytosol. Lysosome. Secreted, extracellular exosome. Secreted. The precursor is cytosolic. In response to inflammasome-activating signals, such as ATP for NLRP3 inflammasome or bacterial flagellin for NLRC4 inflammasome, cleaved and secreted. IL1B lacks any known signal sequence and the pathway(s) of its secretion is(are) not yet fully understood (PubMed:24201029). On the basis of experimental results, several unconventional secretion mechanisms have been proposed. 1. Secretion via secretory lysosomes: a fraction of CASP1 and IL1B precursor may be incorporated, by a yet undefined mec

Diseases

• Inflammation
• Malignant Neoplasms
• Inflammatory Response
• Variable Number Tandem Repeat
• Dysequilibrium Syndrome
• Cholangiocarcinoma
• Malignant Neoplasm Of Stomach
• Arthritis
• Neoplasms
• Diabetes Mellitus
• Carcinogenesis
• Stomach Neoplasms
• Degenerative Polyarthritis

• Infective Disorder
• Innate Immune Response
• Helicobacter Infections
• Endometrial Polyp
• Rheumatoid Arthritis
• Fibrosis
• Bacterial Infections

Pathways

• Pathogenesis
• Inflammatory Response
• Immune Response
• Secretion
• Cytokine Production
• Innate Immune Response
• Localization
• Cell Proliferation
• Methylation
• Parturition
• Angiogenesis
• Fertilization
• Cell Cycle

• Virulence
• Cell Death
• Cell Differentiation
• Dna Methylation
• Response To Lipopolysaccharide
• Reverse Transcription
• Translation

PTMs

• Phosphorylation
• Cleavage
• Methylation
• Demethylation

• Glycosylation
• Acetylation
• Ubiquitination
• Sumoylation

• Oxidation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/IL1B

Boster Bio - The Best Uses Of The IL1B Marker

Boster has announced its new line IL1B antibodies. These antibodies were tested on a variety of platforms with both positive and negative samples. This ensures that they have high affinity and specificity. Boster provides those who review their products with product credits, which they offer to all scientists around the world. Read on to discover the advantages of Boster antibodies. Here are a few of the best uses for the IL1B antibody.

Marker IL1B

The IL1B geneis known as interleukin-1 Beta, is part of the IL-1 family. This protein is involved in host defense and immune responses. The interleukin 1 family plays crucial roles in the pathogenesis of a variety of diseases and is an important mediator in the immune response to different challenges. Boster Bio offers several ELISA kits targeting this gene.

The marker IL1B is bioactive IL-1B molecule , which is found in secreted exosomes as well as shed microvesicles from plasma membrane. This bioactive IL1B has a limited time-to-live in plasma and is destined to distant sites. When stimulated with ATP, THP-1 cells release vesicleless and IL-1B. The IL1B released by these cells follows another process, known as terminal release, which leads to cell death.

Priming and triggering the secretion of IL-1B is a crucial step in the process of healing. After priming, cells have to encounter further DAMP or PAMP, which refers to "danger associated molecular pattern" or "endogenous molecules" released by dead cells. This stimulation is necessary for the active IL-1b molecule to be processed. In the meantime, this process could take a long time and be tedious.

The release of IL-1b occurs through multiple mechanisms that are dependent upon the intensity and duration of the inflammation stimulus. The mechanisms for secretion are classified into three types: rescue and redirect, protected release and terminal release. The particular mechanism chosen is based on the stimulus that triggers inflammation. These three categories are used to define the IL-1B release that occurs. The IL-1B marker is accessible in Boster Bio.

IHC workflow

In immunohistochemistry (IHC), antibodies are used to identify the presence of haptens and antigens in cells. The process exploits the principle that antibodies bind with antigens in biological tissues. Different methods can be employed to visualize the reaction including enzymes. Sample preparation is critical for successful antigen exhibition. It is therefore critical to fixate the sample as quickly as you can to avoid denaturement.

In this study, we used tissue samples from nine patients with IBD. We used tissue digests from each patient in addition to control samples and mock controls. Supplementary Table 10 contains the antibodies that were used in this study.

Inflammasome

The IL1B gene is a typical marker in human tumors, is frequently expressed. It has been recognized as a biomarker that could be used to detect various cancer types including bladder and lung Squamous Cell Cancer. The inflammasome family includes IL1B gene. The tumors from this family are similar in expression levels of IL1B, IC, and NKX2.

Inflammasome clusters are often associated with tumor immunogenicity and resistance immune checkpoint blockade therapies. Tumors with high concentrations of inflammasome clusters are more likely not to respond to ICB treatment, according to the SVM-based Inflammasome classification. Clusters of inflammasomes are likely to be related to TMIT subtyping, which is another way to identify tumors with ICB resistance.

IL1B gene expression is also related to the degree of tumor purity, which indicates the proportion of tumor cells in the surrounding tissue. The gene is highly abundant in cancers in cluster 2 and has a low enrichment of proinflammatory genes. The most abundant genes in cluster 2 are ZBTB16 as well as CASP1. These genes inhibit the inflammation response, resulting in low inflammasome scores. The three most down-regulated miRNAs in cluster 2 are involved in the inflammatory response.

Listeria monocytogenes infection triggers release of IL-1b, a bioactive substance. This marker is released directly across the disintegrating plasma membrane. However, this release is only possible when an infection has been associated with an inflammasome-mediated death. A test for IL-1B can be done to determine whether an individual sufferer has a high or low levels of IL-1b.

Direct method

IL1B is a genetic variant which promotes the recruitment of the cells that have the C-C chemokine receptor type 2 (CCL2) to the breast cancer site. The marker EGFP was made from the IL1B product of PCR. The primer sequence highlighted the T7 promoter. When compared to control cells, EGFP expression is increased in response to IL1B.

The theory was validated in a recent study which involved over 10,000 patients with lung cancer. The patients were treated with a drug that blocked IL-1b. The study was placebo-controlled and randomized. The results indicated that the treatment associated with increased anti-tumor activities. However further research is required to fully comprehend the mechanism of the marker. It is important to understand how the marker functions and how it works, and why blocking IL-1b can be so effective.

When inflammation occurs and inflammation is present, the IL1B marker is activated. The overexpression of IL1B could be a regenerative reaction that is indirect to tissue damage or an indication that the gene plays crucial roles in preparing tissues. However, TUNEL staining is important for understanding the timing of regenerative gene expression. EGFP expression, on the other hand, has a longer half-life that IL1B transcripts.

Activated T-helper lymphocytes produce IL-1b. It stimulates the production certain cytokines in T cells and assists them to grow. It is believed that IL-1b can increase the production of IL-2 which is an important growth factor in T-cells. It promotes the proliferation and survival of T-helper cells (TH2).

Direct method of screening monoclonal antibodies

The direct method for screening monoclonal antibodies can be utilized to aid in the development of new treatments. This involves screening thousands upon thousands of cells in order to determine which ones have the correct functional properties. Although therapeutic antibodies are typically non-internalized, they have to be internalized for them to function. An immediate screening of monoclonal antibody is not the best method to identify hybridomas which secrete desired antibodies.

Flow Cytometry is a method that measures changes in light scatter in order to detect internalization. It also assesses the cytotoxicity. Flow cytometry is a method to determine monoclonal antibody screening. The primary antibody must be isolated to allow direct screening. This method also requires a facility equipped with a fluorescence scanner and radioisotopes. It is not suitable for high throughput screening.

There are a variety of methods that have been developed in molecular biology to screen monoclonal recombinant antibodies that are recombinant. The display of phages is one of the oldest methods. This involves inserting scFv and Fab fragments into cells and allowing them to transform into IgG. This method is suggested by experts in molecular biology to screen antibodies. However it requires a high level of knowledge. Because of this, it is not widely utilized.

This method has many advantages. The number of cells that are being screened is 100 times greater than the number of compounds in chemical libraries. It is also simple to use and doesn't reduce sensitivity or specificity. It is possible to screen multiple antibodies in the same experiment. This technique is an effective tool for early screening since it allows researchers to quickly identify candidates for antibodies that have high affinity. This procedure can be used for a variety of purposes, saving both time and money.